Thomas Björk

Skåne University Hospital — Sweden

Medicine · Health Sciences

24h-index3.8kcitations50works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(32), Prostate Cancer Diagnosis and Treatment(27), Stochastic processes and financial applications(6), Bladder and Urothelial Cancer Treatments(5), Hormonal and reproductive studies(5)

Publications50 total

Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations
Journal of Comparative Effectiveness Research·2014· 13 citedOpen Access
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
BMJ·2013· 278 citedOpen Access
Monte Carlo Euler approximations of HJM term structure financial models
BIT Numerical Mathematics·2012· 3 cited
Monte Carlo Euler approximations of HJM term structure financial models
arXiv (Cornell University)·2012Open Access
Monte Carlo Euler approximations of HJM term structure financial models
ACMAC's PrePrint Repository (Archimedes Center for Modeling, Analysis and Computation)·2012Open Access
A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index
European Urology·2012· 185 citedOpen Access
Toward a rational strategy for prostate cancer screening based on long-term risk of prostate cancer metastases and death: Data from a large, unscreened, population-based cohort followed for up to 30 years.
Journal of Clinical Oncology·2011· 3 cited
1202 CAN AN EARLY PSA RULE OUT SUBSEQUENT ADVANCED PROSTATE CANCER? LONG TERM RISK OF ADVANCED CANCER IN MEN WITH LOW PSA LEVELS AT AGE BELOW 50
The Journal of Urology·2011· 1 cited
986 HOW SOON CAN WE IDENTIFY MEN AT HIGH RISK FOR PROSTATE CANCER DEATH? AN EARLY SURVEILLANCE STRATEGY FOR PROSTATE CANCER
The Journal of Urology·2011· 1 cited
Intra‐individual short‐term variability of prostate‐specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer
British Journal of Urology·2010· 10 citedOpen Access
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study
BMJ·2010· 237 citedOpen Access
982 LIFETIME RISK OF DEATH FROM PROSTATE CANCER PREDICTED BY KALLIKREIN MARKERS IN BLOOD TAKEN AT AGE 60
European Urology Supplements·2010· 1 cited
1725 PSA AT AGE 44-50 PREDICTS LONG-TERM RISK OF PROSTATE CANCER METASTASES IN AN UNSCREENED POPULATION
The Journal of Urology·2010
404 A BONE SCAN INDEX TO QUANTIFY THE EXTENT OF SKELETAL INVOLVEMENT BY TUMOR CAN BE USED TO PREDICT SURVIVAL IN PROSTATE CANCER PATIENTS
The Journal of Urology·2010
Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened Population
Journal of Clinical Oncology·2008· 103 cited
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
BMC Medicine·2008· 120 citedOpen Access
[Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
PubMed·2007· 1 cited
The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically‐based screening strategy
International Journal of Cancer·2007· 50 citedOpen Access
Value of PSA measured in middle age in predicting diagnosis of advanced prostate cancer in an unscreened population
Journal of Clinical Oncology·2007
1876: A Single PSA Measurement in Middle Age Predicts Diagnosis of Advanced Prostate Cancer Up to 25 Years Later in an Unscreened Population
The Journal of Urology·2007
page 1 of 3Next →

Frequent Co-authors

Hans Lilja(31), David Ulmert(19), Andrew J. Vickers(14), Peter T. Scardino(11), Anders Bjartell(9), Per‐Anders Abrahamsson(8), Göran Berglund(8), Jonas Manjer(7), Charlotte Becker(7), Timo Piironen(6), Axel Gerdtsson(5), Peter M. Nilsson(5), Angel M. Serio(5), James A. Eastham(5), Anders Christensson(4), Elyès Jouini(4), Caroline Savage(4), Kim Pettersson(4), Magnus Grabe(4), Arne Forsgren(4)